TY - JOUR
T1 - Update of penetrance estimates in Birt-Hogg-Dubé syndrome
AU - Bruinsma, Fiona Jane
AU - Dowty, James G.
AU - Win, Aung Ko
AU - Goddard, Laura C.
AU - Agrawal, Prachi
AU - Attina', Domenico
AU - Bissada, Nabil
AU - de Luise, Monica
AU - Eisen, Daniel B.
AU - Furuya, Mitsuko
AU - Gasparre, Giuseppe
AU - Genuardi, Maurizio
AU - Gerdes, Anne-Marie
AU - Hansen, Thomas Van Overeem
AU - Houweling, Arjan C.
AU - Johannesma, Paul Christiaan
AU - Lencastre, André
AU - Lim, Derek
AU - Lindor, Noralane M.
AU - Luzzi, Valentina
AU - Lynch, Maeve
AU - Maffé, Antonella
AU - Menko, Fred H.
AU - Michels, Guido
AU - Pulido, Jose S.
AU - Ryu, Jay H.
AU - Sattler, Elke C.
AU - Steinlein, Ortrud K.
AU - Tomassetti, Sara
AU - Tucker, Kathy
AU - Turchetti, Daniela
AU - van de Beek, Irma
AU - van Riel, Lore
AU - van Steensel, Maurice
AU - Zenone, Thierry
AU - Zompatori, Maurizo
AU - Walsh, Jennifer
AU - Bondavalli, Davide
AU - Maher, Eamonn R.
AU - Genetic Susceptibility Working Group I-CONFIRM
AU - Winship, Ingrid M.
N1 - Funding Information:
This work was supported by Cancer Council Victoria via salary support for FJB. ERM acknowledges support from the National Institute for Health Research (NIHR) (Senior Investigator Award and Cambridge NIHR Biomedical Research Centre, BRC-1215–20014). The University of Cambridge received salary support in respect of ERM from the NHS in the East of England through the Clinical Academic Reserve.
Publisher Copyright:
© 2023 BMJ Publishing Group. All rights reserved.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - BACKGROUND: Birt-Hogg-Dubé (BHD) syndrome is a rare genetic syndrome caused by pathogenic or likely pathogenic germline variants in the FLCN gene. Patients with BHD syndrome have an increased risk of fibrofolliculomas, pulmonary cysts, pneumothorax and renal cell carcinoma. There is debate regarding whether colonic polyps should be added to the criteria. Previous risk estimates have mostly been based on small clinical case series. METHODS: A comprehensive review was conducted to identify studies that had recruited families carrying pathogenic or likely pathogenic variants in FLCN. Pedigree data were requested from these studies and pooled. Segregation analysis was used to estimate the cumulative risk of each manifestation for carriers of FLCN pathogenic variants. RESULTS: Our final dataset contained 204 families that were informative for at least one manifestation of BHD (67 families informative for skin manifestations, 63 for lung, 88 for renal carcinoma and 29 for polyps). By age 70 years, male carriers of the FLCN variant have an estimated 19% (95% CI 12% to 31%) risk of renal tumours, 87% (95% CI 80% to 92%) of lung involvement and 87% (95% CI 78% to 93%) of skin lesions, while female carriers had an estimated 21% (95% CI 13% to 32%) risk of renal tumours, 82% (95% CI 73% to 88%) of lung involvement and 78% (95% CI 67% to 85%) of skin lesions. The cumulative risk of colonic polyps by age 70 years old was 21% (95% CI 8% to 45%) for male carriers and 32% (95% CI 16% to 53%) for female carriers. CONCLUSIONS: These updated penetrance estimates, based on a large number of families, are important for the genetic counselling and clinical management of BHD syndrome.
AB - BACKGROUND: Birt-Hogg-Dubé (BHD) syndrome is a rare genetic syndrome caused by pathogenic or likely pathogenic germline variants in the FLCN gene. Patients with BHD syndrome have an increased risk of fibrofolliculomas, pulmonary cysts, pneumothorax and renal cell carcinoma. There is debate regarding whether colonic polyps should be added to the criteria. Previous risk estimates have mostly been based on small clinical case series. METHODS: A comprehensive review was conducted to identify studies that had recruited families carrying pathogenic or likely pathogenic variants in FLCN. Pedigree data were requested from these studies and pooled. Segregation analysis was used to estimate the cumulative risk of each manifestation for carriers of FLCN pathogenic variants. RESULTS: Our final dataset contained 204 families that were informative for at least one manifestation of BHD (67 families informative for skin manifestations, 63 for lung, 88 for renal carcinoma and 29 for polyps). By age 70 years, male carriers of the FLCN variant have an estimated 19% (95% CI 12% to 31%) risk of renal tumours, 87% (95% CI 80% to 92%) of lung involvement and 87% (95% CI 78% to 93%) of skin lesions, while female carriers had an estimated 21% (95% CI 13% to 32%) risk of renal tumours, 82% (95% CI 73% to 88%) of lung involvement and 78% (95% CI 67% to 85%) of skin lesions. The cumulative risk of colonic polyps by age 70 years old was 21% (95% CI 8% to 45%) for male carriers and 32% (95% CI 16% to 53%) for female carriers. CONCLUSIONS: These updated penetrance estimates, based on a large number of families, are important for the genetic counselling and clinical management of BHD syndrome.
KW - Gene Expression
KW - Genetic Predisposition to Disease
KW - Genetic Research
KW - Human Genetics
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150751788&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36849229
U2 - 10.1136/jmg-2022-109104
DO - 10.1136/jmg-2022-109104
M3 - Review article
C2 - 36849229
SN - 0022-2593
VL - 60
SP - 317
EP - 326
JO - Journal of Medical Genetics
JF - Journal of Medical Genetics
IS - 4
ER -